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Edited by Frances ShannonAbstract Myeloid Elf-1 like factor (MEF) is an ETS protein,
which activates the promoters of granulocyte macrophage col-
ony-stimulating factor, interleukin-3, lysozyme, human beta
defensin-2 and perforin. In spite of its many known functions, lit-
tle is known about MEF transcriptional regulation. Here, we
cloned the 5 0-ﬂanking region of human MEF gene and identiﬁed
a TATA-less promoter region at 204/54 which contains 4
putative binding sites for Sp1, two of which are essential in up-
regulating MEF activity. These were proven by EMSA and
blocking Sp1 using RNAi or mithramycin A treatment of
HEK293 cells. Our results suggest that Sp1 constitutively regu-
lates the MEF gene.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The E26 speciﬁc (ETS) family of transcription factors is
found exclusively in multicellular organisms and plays impor-
tant roles in development, diﬀerentiation, angiogenesis and
transformation (recently reviewed in [1]). Myeloid elf-1-like
factor (MEF) or ELF4 or ELFR [2] is a member of the ETS
transcription factor family and is expressed in hematopoietic
and epithelial cells. It was found to activate the promoters of
interleukin-3 and granulocyte-macrophage colony-stimulating
factor [3,4]. We have previously established that MEF consti-
tutively activates the lysozyme gene [5] and also up-regulates
the transcription of human beta-defensin 2 gene in epithelial
cells [6]. The transactivation function of MEF is partly regu-
lated by the promyelocytic leukemia (PML) protein through
their direct interaction and the recruitment of MEF into the
PML nuclear bodies [7,8]. MEF-deﬁcient mice showed a pro-
found reduction in the number and cytolytic activity of the
NK and NK-T cells due to a severely impaired perforin protein
expression. MEF was shown to directly regulate the transcrip-*Corresponding author. Fax: +81 96 371 4405.
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doi:10.1016/j.febslet.2005.04.015tion of the perforin gene in NK cells [9]. We previously demon-
strated that MEF is a candidate tumor suppressor gene in the
X chromosome [10]. The numerous target genes of MEF and
its biological functions signify the importance of this Ets tran-
scription factor. Therefore, we attempted to elucidate the
mechanisms involved in its transcriptional regulation.
Sp1 binds to GC-rich DNA sequences in human gene pro-
moters and regulate a large number of house-keeping and tis-
sue-speciﬁc genes (reviewed in [11–13]). Here, we show that
within the promoter of MEF, two of the four Sp1 binding sites
are important for the regulation of MEF transcription and Sp1
binds to these sites to activate the MEF gene.2. Materials and methods
2.1. Cloning of MEF genomic 5 0 region and construction of luciferase
reporter gene plasmids
The 1.9 kb upstream of MEF gene and part of its 5 0UTR were
ampliﬁed with the primers: Forward: 5 0-CGCGTGTGCA-
GACGTGTCTGTCC-3 0; Reverse: 5 0-GAAGAACCGGCGCCATC-
GACGTACC-30 and Takara LA Taq polymerase with GC buﬀer
(Takara, Japan) using the genomic DNA prepared from HEK293 cells
as template. The PCR product was cloned into pCR2.1 vector using
the TA cloning kit (Invitrogen, Carlsbard, CA). MEF promoter-luc re-
porter plasmid was constructed by subcloning MEF promoter frag-
ment (1911/+181) into the XhoI-HindIII sites of pGL3-Basic vector
(Promega, Madison, WI). Deletion mutants of MEF promoter were
constructed by PCR-based approach using the 1911/+181 construct
as template and inserting the ampliﬁed fragments into pGL3-Basic vec-
tor. All the point mutant constructs were prepared using Quik change
II XL site-directed mutagenesis kit (Stratagene, La Jolla, CA) accord-
ing to the manufacturers instructions. The sequences of primers used
for mutagenesis are shown in Table 1. All mutant plasmids were made
using the 204/+181 construct in pGL3basic vector as template.
Restriction sites were introduced into the mutations for selection;
and the incorporation of the mutation was veriﬁed by restriction diges-
tion and sequencing. All the plasmids used in this study were se-
quenced with ABI3730XL DNA sequencer at the genomics facility
of Macrogen (Seoul, South Korea). The pERV2/Sp1 construct was
kindly provided by Dr. G. Suske.2.2. Cell culture and transient transfection
Human embryonic kidney cells HEK293 obtained from the Ameri-
can Type Culture Collection were maintained in Dulbeccos modiﬁed
Eagles medium supplemented with 10% fetal bovine serum at 37 C
in a humidiﬁed atmosphere of 5% CO2. Transient transfections of plas-
mid DNAs were performed using TransIT-LT-1 reagent (Mirus, Mad-
ison, WI) following the manufacturers recommended protocol as
described in [7]. Small interfering RNAs designed to knock downblished by Elsevier B.V. All rights reserved.
Table 1
Sequences of oligonucleotides used as primer for PCR ampliﬁcation and EMSA probes
Constructs Primers
5 0 MEFprom(-1911_XhoI) 5 0-CTCGAGTGCAGACGTGTCTGTCC-30
5 0 MEFprom(-849_XhoI) 5 0-CTCGAGACGAAACCTTCCCGAGTCC-30
5 0 MEFprom(-386_XhoI) 5 0-CTCGAGCTTTCGCTCGCTCGTTTCG-30
5 0 MEFpromotet(-204_XhoI) 5 0-CTCGAGCCTCCAACTTCCCATTGG-30
5 0 MEFpromoter(-12_XhoI) 5 0-CTCGAGGCTCAACTTCCACTTCTCC-30
MEFpro(full_HindIII) 5 0-AAGCTTCCGGCGCCATCGACGTACC-30
MEFprom MT1_sense 5 0-CGGGCGGGGAGGACTCGAGGGGACGGCGGC-3 0
MEFpromMT1_antisense 5 0-GCCGCCGTCCCCTCGAGTCCTCCCCGCCCG-3 0
MEFprom MT2_sense 5 0-GGAGGAAGGGCGGGTACCGAGGAGGGCGGG-3 0
MEFprom MT2_antisense 5 0-CCCGCCCTCCTCGGTACCCGCCCTTCCTCC-3 0
MEFprom MT3_sense 5 0-GGCGGGGGCAGGCGGTCGACGAGGAAGGG-3 0
MEFprom MT3_antisense 5 0-CCCTTCCTCGTCGACCGCCTGCCCCCGCC-3 0
MEFprom MT4_sense 5 0-CCCGCCCGGACCAGAATTCCCCGGCGCCG-3 0
MEFprom MT4_antisense 5 0-CGGCGCCGGGGAATTCTGGTCCGGGCGGG-3 0
WT1 probe_sense 5 0-GGAGGAAGGGCGGGTACCGAGGAGGGCGGG-3 0
WT1 probe_antisense 5 0-CCCGCCCTCCTCGGTACCCGCCCTTCCTCC-3 0
WT3 probe_sense 5 0-GGCGGGGGCAGGCGGGGGGGGAAGAAGGG-3 0
WT3 probe_antisense 5 0-CCCTTCTTCCCCGCCCGCCTGCCCCCGCC-3 0
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(Invitrogen) according to the manufacturers instructions. A ﬁnal con-
centration of 0.13 lM Sp1 iRNA duplex was transfected into 40% con-
ﬂuent cells, which were harvested 36–44 h after transfection.
2.3. Reporter gene assays
HEK293 cells seeded onto 12-well plates were transfected with
0.2 lg wild-type or mutant MEF promoter in pGL3-basic, together
with a control Renilla luciferase plasmid (Promega). The amount of
co-transfected Sp1 was as indicated in the ﬁgures. Mithramycin A (Sig-
ma, St. Louis, MO) was added 10 h before harvesting the cells. Forty-
eight hours after transfection, cells were assayed for luciferase activity
using a Dual-Luciferase Reporter assay system (Promega) as described
previously [7].
2.4. Western blotting
For analysis of Sp1 and MEF protein expressions, HEK293 cells
transfected with the Sp1 siRNA were used to obtain nuclear extracts
as described earlier [6]. Equal amounts of nuclear extracts (60 lg of
protein) were fractionated on a 7.5% SDS–polyacrylamide gel electro-
phoresis and transferred to polyvinylidene diﬂuoride membrane (Mil-
lipore, Corp., MA). After blocking the membrane with 5% non-fat
milk in 0.1% PBS–Tween, it was incubated with 1:200 dilution of rab-
bit polyclonal antibody against MEF (TransGenic Inc., Japan). The
secondary antibody reaction was carried out with 1:5000 dilution of
HRP-conjugated anti-rabbit IgG (Jackson ImmunoResearch Labora-
tories, Inc., PA). The bound proteins were detected by chemilumines-
cence using ECL (Amersham Pharmacia Biotech, UK). The membrane
was reprobed with 1:500 dilution of goat polyclonal antibody against
Sp1 (Santa Cruz Biotechnology, CA).
2.5. RT-PCR
Total RNA was collected from HEK293 cells treated with mithra-
mycin A or transfected with Sp1 siRNA oligo using Isogen (Nippon-
gene, Japan). RT-PCR experiments were performed with an
RT-PCR kit (Takara, Japan) according to the manufacturers instruc-
tions. The annealing temperature used in PCR was 58 C for MEF and
55 C for Sp1.
2.6. Electrophoresis mobility shift assay
Electrophoresis mobility shift assay was performed as described ear-
lier [15]. Nuclear extracts from HEK293 cells were incubated with
[c-32P]-labeled oligonucleotides representing MEF promoter 63/54
and 91/82 with or without the indicated excess of unlabeled com-
petitors. The sequences of the oligos are listed in Table 1. The
DNA–protein complexes were resolved in 4.5% polyacrylamide gels.
For supershift assays, 2 lg of Sp1 antibody (Santa Cruz) was used.
The migrating bands were visualized by autoradiography using BAS-
2000 (Fuji ﬁlm, Japan).3. Results and discussion
3.1. Cloning the 5 0-ﬂanking region of MEF and analysis of the
putative transcription factor binding sites
To characterize the MEF transcriptional system, we cloned a
genomic DNA fragment containing the 5 0-ﬂanking region of
human MEF gene (GenBank accession number: NT011786).
The cloned fragment spans 1.9 kb upstream of exon 1, down
the length of the ﬁrst exon to 10 bp of the 5 0UTR. Analysis
of the MEF 5 0-ﬂanking region using the TFSEARCH data-
base (http://www.cbrc.jp/research/db/TFSEARCH.html) re-
vealed a GC-rich region that does not contain a TATA box
but has 10 putative binding sites for Sp1 within 849 bp up-
stream from the start of exon 1 which we designated as +1
(Fig. 1A). To determine the probable minimal promoter region
required for transcriptional activity of MEF gene, we gener-
ated deletion constructs that contain 10, 6, and 4 Sp1 sites
(Fig. 1B). These constructs were transfected into HEK293 cells
which highly express MEF [10]. The longest construct 1911/
+181 did not display any activation. However, the activities of
849/+181, 386/+181 and 204/+181 were 6- to 7-fold high-
er than the basal activity. These data suggest that there are
inhibitory elements in the MEF promoter within 1911 to
850. Putative binding sites for NF-jB and AP1 transcription
factors were detected in this region using TFSEARCH data-
base. However, our attempts to block the NF-jB and AP1
activation pathways did not aﬀect MEF transactivation (data
not shown).
On the other hand, the deletion of the region containing the
Sp1 sites, that is, 12/+181 construct, abolished the reporter
activity, implying that the Sp1 sites are important for MEF
promoter activation. The 204/+181 construct having 4 Sp1
sites, exhibited maximum activity (Fig. 1B). Thus, together,
these results indicate that the cis-regulatory elements required
for MEF transcriptional activity are mainly located in the core
promoter region 204 to 12.3.2. Sp1 stimulates MEF promoter activity
Sp1 is known to play a role in the regulation of genes lacking a
functional TATA box. Examples of this are the human andro-
gen receptor [16] and the beta-secretase enzyme [17] that have a
Fig. 1. The 249 bp 5 0 ﬂanking region of MEF contains promoter activity. (A) Nucleotide sequence of the 5 0 ﬂanking region of human MEF gene.
The site indicated (+1) denotes the start site of the ﬁrst exon. The predicted binding sites for Sp1 are marked on the sequence. The lengths of the
diﬀerent promoter constructs are marked by arrows. (B) Deletion analysis of MEF promoter. HEK293 cells were transfected with MEF promoter
deletion constructs and 48 h after, the lysates were harvested for luciferase reporter assays. The reporter activity is expressed as fold activation over
the empty vectors. Values are means ± S.E. from triplicate platings of three independent experiments. The constructs are represented at the left with
circles as the Sp1 binding sites.
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activate transcription. The presence of numerous Sp1 binding
sites in the promoter region of MEF suggested that Sp1 might
be involved in the regulation of MEF activity. Therefore,
we co-transfected the 204/+181 construct and increasing
amounts of Sp1 expressing plasmid into HEK293 cells. Wefound a dose-dependent increase in reporter activity (Fig.
2A). Moreover, we analyzed the eﬀects of mithramycin A, a
drug known to modify GC-rich regions of the DNA and inhibit
Sp1 binding [18]. As shown in Fig. 2B, treatment with mithra-
mycin A down-regulated the activity of MEF. Collectively,
these results suggest a role for Sp1 in regulatingMEF promoter.
Fig. 2. Sp1 up-regulates the activity of MEF. (A) MEF promoter
(204/+181) was co-transfected with indicated amount of Sp1 into
HEK293. Empty vectors were added to ensure a constant input of
DNA. (B) HEK293 cells were transfected with MEF promoter and
treated with mithramycin A for 10 h at the indicated concentrations.
Luciferase activity of the lysates, for both (A) and (B) was determined
48 h after transfection of plasmids and is expressed as fold activation
over the empty vectors. Values are means ± S.E. from triplicate
platings of three independent experiments.
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We next asked which, among the 4 Sp1 sites in 204/+181
region, is/are indispensable for promoter activity. We created
reporter constructs carrying mutated sites and transfectedFig. 3. Two Sp1 sites are essential for the regulation of MEF promoter
activity. 0.2 lg of each mutant plasmid was transfected into HEK293
cells. Luciferase activity of the lysates was determined 48 h after
transfection and is expressed as fold activation over the empty vectors.
The data shown are representative of four independent experiments.
The constructs are represented at the left with circles as the Sp1
binding sites.them into HEK293 cells (Fig. 3). The second and fourth Sp1
binding sites relative to the start site (MT2 and MT4, respec-
tively) seemed not to be essential because the mutation within
these constructs had no eﬀect on promoter activity. In con-
trast, the mutation within the ﬁrst and the third Sp1 binding
sites each led to a moderate decrease in activity compared to
that of the wild-type construct. Consistently, the activity was
completely abolished upon the simultaneous mutations of
the ﬁrst and third Sp1 sites. These results strongly indicate that
Sp1 regulates MEF through these two sites and that each site is
important to attain maximum activity.
3.4. Sp1 binds to the MEF promoter
Having shown that Sp1 sites 1 and 3 are essential for the
induction of transcriptional activity, we next sought to deter-
mine the protein-binding ability of these putative Sp1 elements.Fig. 4. Sp1 binds to two sites (91/82 and 63/54) in the MEF
promoter. (A,B) MEF probes containing the sequences of MEF
promoter 63/54, designated as WT1 and 91/82 designated as
WT3 were labeled with [c-32P]. Binding assays were performed using
8–10 lg HEK293 nuclear extract and 2 lg of poly(dI-dC) with or
without an excess of unlabeled WT, MT, and Sp1 consensus site (A) or
2 lg of Sp1 antibody (B). The data shown are representative of two
independent experiments.
Fig. 5. Sp1 siRNA and mithramycin A down-regulated MEF endogenous expression. (A) HEK293 cells were treated with the indicated
concentration of mithramycin A 10 h before RNA recovery. Total RNA extracts were subjected to semi-quantitative RT-PCR. Right panel,
Quantitative analysis of MEF (40 cycles) and GAPDH (25 cycles) gene expression was performed using Image Gauge software (Fuji ﬁlm). Relative
MEF mRNA expression levels were normalized to the level of GAPDH that served as an internal control. (B) HEK293 cells were transfected with the
indicated concentration of Sp1 siRNA oligo. Total RNA lysates were collected 44 h after and subjected to RT-PCR. (C) Western blotting was
performed on nuclear extracts of HEK293 untransfected or transfected with Sp1 siRNA oligo. Blotted membranes were reacted with anti-MEF or
anti-Sp1 antibodies.
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formed EMSA experiments with 32P-labeled oligonucleotides
representing the ﬁrst and the third Sp1 binding sites of the pro-
moter (represented as WT1 and WT3, respectively). A slow
migrating band was observed which could be competed specif-
ically by 50-fold molar excess of unlabeled oligonucleotides
WT1 and WT3 but not by an oligonucleotide whose Sp1 con-
sensus site has been mutated (MT1 and MT3) (Fig. 4A). To
conﬁrm that the labeled probe contains Sp1 binding site, an ex-
cess of cold Sp1 consensus oligonucleotide was also used as a
competitor. Many studies have demonstrated that Sp1 and
Sp3 recognize GC- or GT-boxes and some promoters are dually
regulated by these closely related proteins (reviewed in [19,20]).
Therefore, we examined whether there is a preferential binding
for Sp1 in 63/54 and 91/82 regions. In our gel shift anal-
ysis, the incubation of the DNA–protein complex with Sp1
antibody but not Sp3 antibody was able to shift up the migrat-
ing bands (Fig. 4B and data not shown). The binding of Sp3 or
other Sp1-related transcription factors is cellular- and pro-
moter-dependent [19]. In the case of MEF, it is likely that
Sp1 is the essential factor, which binds to the GC sequences.
3.5. Blocking Sp1 down-regulates MEF endogenous expression
To illustrate the biological importance of Sp1 in MEF gene
regulation, we blocked Sp1 expression and binding, and exam-
ined MEF endogenous expression. The treatment of cells with
mithramycin A induced a decrease of RNA transcripts as de-
tected by semi-quantitative RT-PCR (Fig. 5A). We also uti-
lized RNA interference technique [14] to knock downintracellular Sp1. Expressions of endogenous MEF RNA
(Fig. 5B) and MEF protein (Fig. 5C) were eﬀectively blocked
by Sp1 siRNA transfection. These data demonstrate the
involvement of Sp1 in regulating the human MEF gene.
In summary, we show here that the 5 0-ﬂanking region of
MEF is GC-rich, wherein putative Sp1 consensus sites abound.
MEF is mainly regulated by the Sp1 transcription factor, as
proven by Sp1 siRNA, through the direct binding of Sp1 to
two sites of the MEF promoter region. The cluster of GCs up-
stream of MEF might also be a target for methylation [21], a
modiﬁcation which could be responsible for the silencing of
MEF gene in cancer cells [10]. We are currently investigating
this possibility. Because MEF is a regulator of perforin, lyso-
zyme and human beta-defensin2 genes, these ﬁndings have
important implications on the role of Sp1, albeit indirect, in in-
nate immunity.
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